Persistent fatigue induced by interferon-alpha: a novel, inflammation-based, proxy model of chronic fatigue syndrome

[1]  M. Henderson,et al.  Depression and anxiety in patients receiving interferon-alpha: The role of illness perceptions , 2018, Journal of health psychology.

[2]  C. Pariante,et al.  Interferon-Alpha Reduces Human Hippocampal Neurogenesis and Increases Apoptosis via Activation of Distinct STAT1-Dependent Mechanisms , 2017, The international journal of neuropsychopharmacology.

[3]  C. Pariante,et al.  Rescue of IL-1β-induced reduction of human neurogenesis by omega-3 fatty acids and antidepressants , 2017, Brain, Behavior, and Immunity.

[4]  Mark M. Davis,et al.  Cytokine signature associated with disease severity in chronic fatigue syndrome patients , 2017, Proceedings of the National Academy of Sciences.

[5]  Andrew H. Miller,et al.  A systematic review of the association between fatigue and genetic polymorphisms , 2017, Brain, Behavior, and Immunity.

[6]  C. Pariante,et al.  Genetic Contributions of Inflammation to Depression , 2016, Neuropsychopharmacology.

[7]  M. Hotopf,et al.  Transcriptomics in Interferon-α-Treated Patients Identifies Inflammation-, Neuroplasticity- and Oxidative Stress-Related Signatures as Predictors and Correlates of Depression , 2016, Neuropsychopharmacology.

[8]  M. Maes,et al.  The Many Neuroprogressive Actions of Tryptophan Catabolites (TRYCATs) that may be Associated with the Pathophysiology of Neuro-Immune Disorders. , 2016, Current pharmaceutical design.

[9]  M. Buckland,et al.  Chronic fatigue syndrome and circulating cytokines: A systematic review , 2015, Brain, Behavior, and Immunity.

[10]  D. Kriz,et al.  A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C. , 2015, Journal of psychosomatic research.

[11]  M. Maes,et al.  Biological phenotypes underpin the physio‐somatic symptoms of somatization, depression, and chronic fatigue syndrome , 2014, Acta psychiatrica Scandinavica.

[12]  R. Dantzer,et al.  The neuroimmune basis of fatigue , 2014, Trends in Neurosciences.

[13]  Max Hopwood.  Perspectives of a self-selected sample of former patients on the long-term health outcomes of interferon-based hepatitis C treatments: an exploratory study , 2013, Psychology, health & medicine.

[14]  T. Chalder,et al.  Childhood stressors in the development of fatigue syndromes: a review of the past 20 years of research , 2013, Psychological Medicine.

[15]  J. Hoofnagle,et al.  Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study. , 2012, Journal of hepatology.

[16]  M. Maes,et al.  Inflammatory and Cell-Mediated Immune Biomarkers in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Depression: Inflammatory Markers Are Higher in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome than in Depression , 2012, Psychotherapy and Psychosomatics.

[17]  M. Maes,et al.  Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression , 2012, Neuroscience & Biobehavioral Reviews.

[18]  U. Vollmer-Conna,et al.  Genetic associations of fatigue and other symptom domains of the acute sickness response to infection , 2011, Brain, Behavior, and Immunity.

[19]  M. Hotopf,et al.  Premorbid risk markers for chronic fatigue syndrome in the 1958 British birth cohort. , 2011, The British journal of psychiatry : the journal of mental science.

[20]  M. Meeus,et al.  Treatment of central sensitization in patients with ‘unexplained’ chronic pain: what options do we have? , 2011, Expert opinion on pharmacotherapy.

[21]  Matteo Cella,et al.  Measuring fatigue in clinical and community settings. , 2010, Journal of psychosomatic research.

[22]  U. Nater,et al.  Neuroendocrine and Immune Contributors to Fatigue , 2010, PM & R : the journal of injury, function, and rehabilitation.

[23]  M. Hotopf,et al.  Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-α and ribavirin treatment , 2009, Molecular Psychiatry.

[24]  Jin-Mann S. Lin,et al.  Association of peripheral inflammatory markers with chronic fatigue in a population-based sample , 2009, Brain, Behavior, and Immunity.

[25]  I. Hickie,et al.  Cytokine polymorphisms have a synergistic effect on severity of the acute sickness response to infection. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  D. Fuchs,et al.  IFN-gamma mediated pathways in patients with fatigue and chronic active Epstein Barr virus-infection. , 2008, Journal of affective disorders.

[27]  M. Hotopf,et al.  The relationship between prior psychiatric disorder and chronic fatigue: evidence from a national birth cohort study , 2007, Psychological Medicine.

[28]  I. Hickie,et al.  Postinfective fatigue syndrome is not associated with altered cytokine production. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  M. Alter,et al.  Epidemiology of hepatitis C virus infection. , 2007, World journal of gastroenterology.

[30]  Richie Poulton,et al.  Childhood maltreatment predicts adult inflammation in a life-course study , 2007, Proceedings of the National Academy of Sciences.

[31]  James F. Jones,et al.  Early adverse experience and risk for chronic fatigue syndrome: results from a population-based study. , 2006, Archives of general psychiatry.

[32]  I. Hickie,et al.  Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study , 2006, BMJ : British Medical Journal.

[33]  M. Cuccia,et al.  A first study of cytokine genomic polymorphisms in CFS: Positive association of TNF-857 and IFNgamma 874 rare alleles. , 2006, Clinical and experimental rheumatology.

[34]  A. Bifulco,et al.  The childhood experience of care and abuse questionnaire (CECA.Q): validation in a community series. , 2005, The British journal of clinical psychology.

[35]  M. Hotopf,et al.  Psychopathological symptoms during interferon-α and ribavirin treatment: effects on virologic response , 2005, Molecular Psychiatry.

[36]  Andrew H. Miller,et al.  Cytokines and psychopathology: Lessons from interferon-α , 2004, Biological Psychiatry.

[37]  I. Hickie,et al.  Production of pro-inflammatory cytokines correlates with the symptoms of acute sickness behaviour in humans , 2004, Psychological Medicine.

[38]  A. House,et al.  Life events, difficulties and dilemmas in the onset of chronic fatigue syndrome: a case–control study , 2003, Psychological Medicine.

[39]  S. Wessely,et al.  A systematic review and critical evaluation of the immunology of chronic fatigue syndrome. , 2003, Journal of psychosomatic research.

[40]  L. Jason,et al.  Comparing Symptoms of Chronic Fatigue Syndrome in a Community-Based Versus Tertiary Care Sample , 2003, Journal of health psychology.

[41]  M. Hotopf,et al.  Predictors of fatigue following the onset of infectious mononucleosis , 2003, Psychological Medicine.

[42]  M. Hotopf,et al.  Recovery from infectious mononucleosis: a case for more than symptomatic therapy? A systematic review. , 2002, The British journal of general practice : the journal of the Royal College of General Practitioners.

[43]  T. Pollmächer,et al.  Low levels of circulating inflammatory cytokines—Do they affect human brain functions? , 2002, Brain, Behavior, and Immunity.

[44]  D. Bhugra,et al.  Social environment, ethnicity and schizophrenia , 2002, Social Psychiatry and Psychiatric Epidemiology.

[45]  C. Nemeroff,et al.  Neurobehavioral Effects of Interferon-α in Cancer Patients: Phenomenology and Paroxetine Responsiveness of Symptom Dimensions , 2002, Neuropsychopharmacology.

[46]  D. Crawford,et al.  Predictions and associations of fatigue syndromes and mood disorders that occur after infectious mononucleosis , 2001, The Lancet.

[47]  A. Rush,et al.  The Inventory of Depressive Symptomatology (IDS): psychometric properties , 1996, Psychological Medicine.

[48]  S. Wessely,et al.  Development of a fatigue scale. , 1993, Journal of psychosomatic research.

[49]  M. Sharpe,et al.  A Report–Chronic Fatigue Syndrome: Guidelines for Research , 1991, Journal of the Royal Society of Medicine.

[50]  T. Brugha,et al.  The List of Threatening Experiences: the reliability and validity of a brief life events questionnaire , 1990, Acta psychiatrica Scandinavica.

[51]  C. Pariante,et al.  Fibromyalgia and chronic fatigue: the underlying biology and related theoretical issues. , 2015, Advances in psychosomatic medicine.

[52]  M. Maes,et al.  Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2,3-dioxygenase and lowered kynurenine aminotransferase activity. , 2011, Neuro endocrinology letters.

[53]  James F. Jones,et al.  Childhood trauma and risk for chronic fatigue syndrome: association with neuroendocrine dysfunction. , 2009, Archives of general psychiatry.

[54]  J. Stirling,et al.  Cannabis-Induced Psychotic-Like Experiences Are Associated with High Schizotypy , 2005 .

[55]  D. Bhugra,et al.  Social environment, ethnicity and schizophrenia. A case-control study. , 2002, Social psychiatry and psychiatric epidemiology.

[56]  D. Musselman,et al.  Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. , 2002, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[57]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[58]  I. Salit.  Precipitating factors for the chronic fatigue syndrome. , 1997, Journal of psychiatric research.